Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s):  FENC

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.


TSX:FRX - Post by User

Comment by Brinkleyon May 04, 2014 11:09am
143 Views
Post# 22522359

RE:NO SHORT INTEREST

RE:NO SHORT INTERESTThere is a number of reasons 

- ASCO conference will have results of COG trial and interim findings on SIOPEL.  The top line of the COG trial was posted by mistake last month.  It showed a 50% decrease in the instances of hearing loss.  I'm sure the presentation at ASCO will go into far more detail.

- There is a very high percentage of insider ownership.  around 60-70%  that means there isn't very much for sale.  A little bit of interest in the stock will move it up very quickley (as we are seeing now)

- 2 very substantial additions to the board.  The 2 new board members are very experienced.  I have to think that if they decided to join then they see real potential.  

- I have a valuation for my own use.  I won't share it but I would encourage everyone to do their own analysis and come up with one.  I'm sure it will be no where close to the current market cap of $40million.

- I have also heard a rumour about a Nasdaq up list.  

- Proxy for the AGM should be out soon.  There may be some interesting things in that.  I think there is a name change coming.
Bullboard Posts